At the beginning of January, two major milestones of one of our internal R&D projects were reached. In our search for new preserving agents we both succeeded in identifying three new, more active compounds and, on the other hand, we could prove their low toxicity in vitro.

Both aspects are of tremendous importance as we are aiming at applications in ophthalmic and other topical APIs. The currently used preserving excipients either do not exhibit a broad antibiotic activity profile (against fungi & microbes) or they show side effects which can not be neglected, especially with longer treatment schemes.

These results back our confidence to finally offer effective and benign alternatives in this important field within the next 1-2 years.